Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTSR1 | P30989 | 11/20 | 0.56 |
| ▸ | NTSR2 | O95665 | 9/20 | 0.56 |
| ▸ | SORT1 | Q99523 | 4/20 | 0.55 |
| ▸ | F2R | P25116 | 2/20 | 0.52 |
| ▸ | NPY1R | P25929 | 1/20 | 0.51 |
| ▸ | NPY2R | P49146 | 1/20 | 0.51 |
| ▸ | NPY4R | P50391 | 1/20 | 0.51 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.50 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.50 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29440668 | 0.89 | PLK1 (0.50) | NTSR1NTSR2SORT1OPRM1OPRK1 | |
| SCHEMBL29496063 | 0.88 | NTSR1 (0.54) | NTSR1NTSR2OPRD1 | |
| SCHEMBL29551878 | 0.85 | OPRD1 (0.56) | NTSR1NTSR2SORT1NPY1RNPY2R | |
| SCHEMBL31179920 | 0.83 | NTSR1 (0.51) | NTSR1NTSR2SORT1NPY1RNPY2R | |
| SCHEMBL29594229 | 0.83 | GRB2 (0.53) | NTSR1NTSR2SORT1F2RCAPN1 | |
| SCHEMBL29375772 | 0.83 | GRB2 (0.57) | NTSR1NTSR2SORT1F2RCAPN1 | |
| SCHEMBL29590984 | 0.82 | NTSR2 (0.49) | NTSR1NTSR2SORT1CAPN1 | |
| SCHEMBL29427923 | 0.81 | EPHA2 (0.49) | NTSR1NTSR2SORT1NPY1RNPY2R | |
| SCHEMBL29392907 | 0.79 | NTSR1 (0.57) | NTSR1NTSR2SORT1NPY1ROPRM1 | |
| SCHEMBL31696336 | 0.78 | XIAP (0.47) | NTSR1NTSR2SORT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260097005-A1 | KETAMINE AND KETAMINE/NAP FOR TREATMENT OF ADNP SYNDROME AND RELATED NEUROLOGICAL CONDITIONS | ADNP KIDS RES FOUNDATION (US) | 2026-04-09 | — | — | US | disclosed |
| US-12502363-B2 | Ketamine and ketamine/nap for treatment of ADNP syndrome and related neurological conditions | ADNP Kids Research Foundation (US) | 2025-12-23 | — | — | US | disclosed |
| US-20250032581-A1 | COMPOSITIONS AND ARTICLES COMPRISING AN ADNF POLYPEPTIDE | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2025-01-30 | — | — | US | disclosed |
| US-20250032580-A1 | USE OF ADNF POLYPEPTIDES IN THERAPY | UNIV RAMOT (IL) | 2025-01-30 | — | — | US | disclosed |
| EP-3488837-B1 | ELECTROPORATION APPARATUS FOR PROVIDING AGENTS TO THE COCHLEA | NEWSOUTH INNOVATIONS PTY LTD (AU) | 2024-11-27 | — | — | EP | disclosed |
| EP-4313117-A1 | USE OF ADNF POLYPEPTIDES IN THERAPY | Ramot at Tel-Aviv University Ltd. (IL) | 2024-02-07 | — | — | EP | disclosed |
| WO-2022201167-A1 | USE OF ADNF POLYPEPTIDES IN THERAPY | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2022-09-29 | — | — | WO | disclosed |
| US-20220257536-A1 | KETAMINE AND KETAMINE/NAP FOR TREATMENT OF ADNP SYNDROME AND RELATED NEUROLOGICAL CONDITIONS | DAVIS, Matthew Christopher | 2022-08-18 | — | — | US | disclosed |
| EP-3979995-A1 | KETAMINE AND KETAMINE/NAP FOR TREATMENT OF ADNP SYNDROME AND RELATED NEUROLOGICAL CONDITIONS | ADNP Kids Research Foundation (US) | 2022-04-13 | — | — | EP | disclosed |
| EP-3395372-B1 | GLUTATHIONE-BASED DRUG DELIVERY SYSTEM | ENHANX BIOPHARM INC (TW) | 2022-04-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260097005-A1 | KETAMINE AND KETAMINE/NAP FOR TREATMENT OF ADNP SYNDROME AND RELATED NEUROLOGICAL CONDITIONS | S100P, S100A10, CAPNS1 | NTSR1 1056/4885NTSR2 1525/4885SORT1 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.